{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:45:41Z","timestamp":1761061541285,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12328-021-01558-5","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T17:02:52Z","timestamp":1637600572000},"page":"177-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy"],"prefix":"10.1007","volume":"15","author":[{"given":"Atsushi","family":"Naganuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Yasuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsushi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-7093","authenticated-orcid":false,"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"1558_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1558_CR2","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"1558_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/ph14010036","volume":"14","author":"T Hatanaka","year":"2021","unstructured":"Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for hepatocellular carcinoma: a literature review. Pharmaceuticals. 2021;14:36.","journal-title":"Pharmaceuticals"},{"key":"1558_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000368142","volume":"87","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure\/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87:22\u201331.","journal-title":"Oncology"},{"key":"1558_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"1558_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"1558_CR7","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","volume":"14","author":"J Matsui","year":"2008","unstructured":"Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14:5459\u201365.","journal-title":"Clin Cancer Res"},{"key":"1558_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10120-016-0633-1","volume":"20","author":"Y Sato","year":"2017","unstructured":"Sato Y, Ohnuma H, Nobuoka T, et al. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer. 2017;20:517\u201326.","journal-title":"Gastric Cancer"},{"key":"1558_CR9","doi-asserted-by":"publisher","first-page":"e170278","DOI":"10.1001\/jamaoncol.2017.0278","volume":"3","author":"G Tomasello","year":"2017","unstructured":"Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3:e170278.","journal-title":"JAMA Oncol"},{"key":"1558_CR10","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.21873\/anticanres.13703","volume":"39","author":"Y Morine","year":"2019","unstructured":"Morine Y, Ikemoto T, Iwahashi S, et al. Clinical impact of FOLFOXIRI aiming for conversion surgery in unresectable multiple colorectal liver metastasis. Anticancer Res. 2019;39:5089\u201396.","journal-title":"Anticancer Res"},{"key":"1558_CR11","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.21873\/anticanres.13768","volume":"39","author":"N Sato","year":"2019","unstructured":"Sato N, Beppu T, Kinoshita K, et al. Conversion hepatectomy for huge hepatocellular carcinoma with arterioportal shunt after chemoembolization and lenvatinib therapy. Anticancer Res. 2019;39:5695\u2013701.","journal-title":"Anticancer Res"},{"key":"1558_CR12","doi-asserted-by":"publisher","first-page":"e22782","DOI":"10.1097\/MD.0000000000022782","volume":"99","author":"T Tomonari","year":"2020","unstructured":"Tomonari T, Sato Y, Tanaka H, et al. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: three case reports. Medicine (Baltimore). 2020;99:e22782.","journal-title":"Medicine (Baltimore)"},{"key":"1558_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s40792-020-01078-3","volume":"6","author":"Y Ohya","year":"2020","unstructured":"Ohya Y, Hayashida S, Tsuji A, et al. Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy. Surg Case Rep. 2020;6:318.","journal-title":"Surg Case Rep"},{"key":"1558_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000506202","volume":"9","author":"R Matsuki","year":"2020","unstructured":"Matsuki R, Kawai K, Suzuki Y, et al. Pathological complete response in conversion hepatectomy induced by lenvatinib for advanced hepatocellular carcinoma. Liver Cancer. 2020;9:358\u201360.","journal-title":"Liver Cancer"},{"key":"1558_CR15","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.4254\/wjh.v12.i12.1349","volume":"12","author":"H Yokoo","year":"2020","unstructured":"Yokoo H, Takahashi H, Hagiwara M, et al. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: a case report. World J Hepatol. 2020;12:1349\u201357.","journal-title":"World J Hepatol"},{"key":"1558_CR16","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1007\/s12328-021-01470-y","volume":"14","author":"R Sugimoto","year":"2021","unstructured":"Sugimoto R, Inada H, Tanaka Y, et al. Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma. Clin J Gastroenterol. 2021;14:1484\u201390.","journal-title":"Clin J Gastroenterol"},{"key":"1558_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4254\/wjh.v13.i3.384","volume":"13","author":"K Takahashi","year":"2021","unstructured":"Takahashi K, Kim J, Takahashi A, et al. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: a case report. World J Hepatol. 2021;13:384\u201392.","journal-title":"World J Hepatol"},{"key":"1558_CR18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000510754","volume":"99","author":"D Yamashige","year":"2021","unstructured":"Yamashige D, Kawamura Y, Kobayashi M, et al. Potential and clinical significance of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography for evaluating liver cancer response to lenvatinib treatment. Oncology. 2021;99:169\u201376.","journal-title":"Oncology"},{"key":"1558_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF00203951","volume":"17","author":"JH Park","year":"1994","unstructured":"Park JH, Kim SH, Han JK, et al. Transcatheter arterial embolization of unresectable renal cell carcinoma with a mixture of ethanol and iodized oil. Cardiovasc Intervent Radiol. 1994;17:323\u20137.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1558_CR20","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.3748\/wjg.v16.i45.5766","volume":"16","author":"YK Gu","year":"2010","unstructured":"Gu YK, Luo RG, Huang JH, et al. Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. World J Gastroenterol. 2010;16:5766\u201372.","journal-title":"World J Gastroenterol"},{"key":"1558_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.22575\/interventionalradiology.3-1G3","volume":"3","author":"T Saguchi","year":"2018","unstructured":"Saguchi T, Arai Y, Kamei S, et al. Guidelines for absolute ethanol for use in vascular embolization, 2016 edition. Interv Radiol. 2018;3:44\u201365.","journal-title":"Interv Radiol"},{"key":"1558_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000499715","volume":"97","author":"K Kodama","year":"2019","unstructured":"Kodama K, Kawaoka T, Namba M, et al. Correlation between early tumor marker response and imaging response in patients with advanced hepatocellular carcinoma treated with lenvatinib. Oncology. 2019;97:75\u201381.","journal-title":"Oncology"},{"key":"1558_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/hepr.13452","volume":"50","author":"T Kuzuya","year":"2020","unstructured":"Kuzuya T, Ishigami M, Ito T, et al. Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatol Res. 2020;50:374\u201381.","journal-title":"Hepatol Res"},{"key":"1558_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/cam4.1909","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Kariyama K, et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: multicenter analysis. Cancer Med. 2019;8:137\u201346.","journal-title":"Cancer Med"},{"key":"1558_CR25","doi-asserted-by":"crossref","unstructured":"Shindoh J, Kawamura Y, Kobayashi Y, et al. Prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma. Ann Surg Oncol. 2021. (Online ahead of print).","DOI":"10.1245\/s10434-021-09974-0"},{"key":"1558_CR26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000510911","volume":"99","author":"S Uchida-Kobayashi","year":"2021","unstructured":"Uchida-Kobayashi S, Kageyama K, Yamamoto A, et al. Lenvatinib-induced tumor-related hemorrhages in patients with large hepatocellular carcinomas. Oncology. 2021;99:186\u201391.","journal-title":"Oncology"},{"key":"1558_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/hepr.13582","volume":"51","author":"E Rodriguez De Santiago","year":"2021","unstructured":"Rodriguez De Santiago E, Tellez L, et al. Hepatocellular carcinoma after Fontan surgery: a systematic review. Hepatol Res. 2021;51:116\u201334.","journal-title":"Hepatol Res"},{"key":"1558_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/hepr.13500","volume":"50","author":"T Sagawa","year":"2020","unstructured":"Sagawa T, Kogiso T, Sugiyama H, et al. Characteristics of hepatocellular carcinoma arising from Fontan-associated liver disease. Hepatol Res. 2020;50:853\u201362.","journal-title":"Hepatol Res"},{"key":"1558_CR29","doi-asserted-by":"publisher","first-page":"21742","DOI":"10.1038\/s41598-020-78840-y","volume":"10","author":"T Kogiso","year":"2020","unstructured":"Kogiso T, Tokushige K. Fontan-associated liver disease and hepatocellular carcinoma in adults. Sci Rep. 2020;10:21742.","journal-title":"Sci Rep"},{"key":"1558_CR30","doi-asserted-by":"publisher","first-page":"E140","DOI":"10.1111\/j.1440-1754.2010.01932.x","volume":"48","author":"J Rosenbaum","year":"2012","unstructured":"Rosenbaum J, Vrazas J, Lane GK, et al. Cardiac cirrhosis and hepatocellular carcinoma in a 13-year-old treated with doxorubicin microbead transarterial chemoembolization. J Paediatr Child Health. 2012;48:E140\u20133.","journal-title":"J Paediatr Child Health"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01558-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01558-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01558-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:26:14Z","timestamp":1673828774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01558-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01558-5","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"5 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest in association with the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The written informed consent was obtained from patient for this case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}